CZ291774B6 - Způsob racemizace opticky čistého nebo obohaceného piperazin-2-terc-butylkarboxamidového substrátu - Google Patents

Způsob racemizace opticky čistého nebo obohaceného piperazin-2-terc-butylkarboxamidového substrátu Download PDF

Info

Publication number: CZ291774B6
Authority: CZ; Czechia
Prior art keywords: tert; salt; formula; substrate; process according
Prior art date: 1994-02-04

Application number

CZ19962272A

Other languages

Czech (cs)

English (en)

Other versions

CZ227296A3 (en

Inventor

Kai Rossen

David Askin

Paul Reider

Richard J. Varsolona

Ralph Volante

Original Assignee

Merck And Co., Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-04

Filing date

1995-01-30

Publication date

2003-05-14

1995-01-30 Application filed by Merck And Co., Inc. filed Critical Merck And Co., Inc.

1997-01-15 Publication of CZ227296A3 publication Critical patent/CZ227296A3/cs

2003-05-14 Publication of CZ291774B6 publication Critical patent/CZ291774B6/cs

Links

238000000034 method Methods 0.000 title claims abstract description 68
239000000758 substrate Substances 0.000 title claims abstract description 26
230000006340 racemization Effects 0.000 title abstract description 23
150000003839 salts Chemical class 0.000 claims abstract description 56
239000002904 solvent Substances 0.000 claims abstract description 23
239000003795 chemical substances by application Substances 0.000 claims abstract description 20
150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 10
229910052751 metal Inorganic materials 0.000 claims abstract description 8
239000002184 metal Substances 0.000 claims abstract description 8
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 91
239000000203 mixture Substances 0.000 claims description 64
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 41
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 41
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 26
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 23
229910052708 sodium Inorganic materials 0.000 claims description 20
239000011734 sodium Substances 0.000 claims description 20
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 19
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 19
238000006243 chemical reaction Methods 0.000 claims description 18
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 15
-1 alkyl lithium Chemical compound 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 12
229910052744 lithium Inorganic materials 0.000 claims description 12
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 11
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
150000004703 alkoxides Chemical class 0.000 claims description 9
125000003118 aryl group Chemical group 0.000 claims description 9
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
229910052799 carbon Inorganic materials 0.000 claims description 7
125000001072 heteroaryl group Chemical group 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
150000001408 amides Chemical class 0.000 claims description 6
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical class C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 5
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 5
239000011591 potassium Substances 0.000 claims description 5
229910052700 potassium Inorganic materials 0.000 claims description 5
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
239000003153 chemical reaction reagent Substances 0.000 claims description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 4
238000011065 in-situ storage Methods 0.000 claims description 4
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 4
MXIRPJHGXWFUAE-UHFFFAOYSA-N lithium;propan-1-olate Chemical compound [Li+].CCC[O-] MXIRPJHGXWFUAE-UHFFFAOYSA-N 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
AWDMDDKZURRKFG-UHFFFAOYSA-N potassium;propan-1-olate Chemical compound [K+].CCC[O-] AWDMDDKZURRKFG-UHFFFAOYSA-N 0.000 claims description 4
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
150000001924 cycloalkanes Chemical class 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 3
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims description 3
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 claims description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 3
239000011592 zinc chloride Substances 0.000 claims description 3
235000005074 zinc chloride Nutrition 0.000 claims description 3
150000001491 aromatic compounds Chemical class 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 claims description 2
229910001623 magnesium bromide Inorganic materials 0.000 claims description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 1
125000001033 ether group Chemical group 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 44
238000002360 preparation method Methods 0.000 abstract description 16
239000000543 intermediate Substances 0.000 abstract description 15
239000004030 hiv protease inhibitor Substances 0.000 abstract description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 119
239000000243 solution Substances 0.000 description 53
235000019439 ethyl acetate Nutrition 0.000 description 40
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 30
239000000047 product Substances 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
229940044613 1-propanol Drugs 0.000 description 27
239000002585 base Substances 0.000 description 19
239000000463 material Substances 0.000 description 18
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
229910052757 nitrogen Inorganic materials 0.000 description 15
239000007787 solid Substances 0.000 description 15
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
150000004885 piperazines Chemical class 0.000 description 13
229920006395 saturated elastomer Polymers 0.000 description 12
239000000725 suspension Substances 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 11
239000012074 organic phase Substances 0.000 description 11
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
239000000126 substance Substances 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
239000012065 filter cake Substances 0.000 description 8
NASIOHFAYPRIAC-JTQLQIEISA-N tert-butyl (3s)-3-(tert-butylcarbamoyl)piperazine-1-carboxylate Chemical compound CC(C)(C)NC(=O)[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 NASIOHFAYPRIAC-JTQLQIEISA-N 0.000 description 8
208000030507 AIDS Diseases 0.000 description 7
241000725303 Human immunodeficiency virus Species 0.000 description 7
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
229960000583 acetic acid Drugs 0.000 description 7
238000010992 reflux Methods 0.000 description 7
238000004809 thin layer chromatography Methods 0.000 description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
108010010369 HIV Protease Proteins 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
238000004296 chiral HPLC Methods 0.000 description 6
238000001514 detection method Methods 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
230000014759 maintenance of location Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000003921 oil Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
241000700605 Viruses Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 5
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 4
208000037357 HIV infectious disease Diseases 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000004821 distillation Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
150000004682 monohydrates Chemical class 0.000 description 4
229960005335 propanol Drugs 0.000 description 4
QQWYQAQQADNEIC-RVDMUPIBSA-N tert-butyl [(z)-[cyano(phenyl)methylidene]amino] carbonate Chemical compound CC(C)(C)OC(=O)O\N=C(/C#N)C1=CC=CC=C1 QQWYQAQQADNEIC-RVDMUPIBSA-N 0.000 description 4
MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
239000012467 final product Substances 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
150000002924 oxiranes Chemical class 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
239000002699 waste material Substances 0.000 description 3
CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
CNQCWYFDIQSALX-UHFFFAOYSA-N 3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
AIHIHVZYAAMDPM-QMMMGPOBSA-N [(2s)-oxiran-2-yl]methyl 3-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)OC[C@H]2OC2)=C1 AIHIHVZYAAMDPM-QMMMGPOBSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000002024 ethyl acetate extract Substances 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
108700004029 pol Genes Proteins 0.000 description 2
101150088264 pol gene Proteins 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000004448 titration Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
AUYBSFAHQLKXSW-UHFFFAOYSA-N 1,2-dichloroethane;3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.ClCCCl.CCN=C=NCCCN(C)C AUYBSFAHQLKXSW-UHFFFAOYSA-N 0.000 description 1
LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
CXRIRCXHLHYHFU-UHFFFAOYSA-N 1,2-dimethoxyethane;n,n-dimethylformamide Chemical compound CN(C)C=O.COCCOC CXRIRCXHLHYHFU-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
FPXOBQQMHSMJMN-UHFFFAOYSA-N 2,2-dimethyl-1-piperazin-1-ylpropan-1-one Chemical compound CC(C)(C)C(=O)N1CCNCC1 FPXOBQQMHSMJMN-UHFFFAOYSA-N 0.000 description 1
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 1
ADVCEUPBLBYYEF-UHFFFAOYSA-N 4-amino-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2C(N)=C(O)C(S(O)(=O)=O)=CC2=C1 ADVCEUPBLBYYEF-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
125000006847 BOC protecting group Chemical group 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
XRPHFZRZETURBH-UHFFFAOYSA-N C(C)(C)(C)N.C(C(=O)Cl)(=O)Cl Chemical compound C(C)(C)(C)N.C(C(=O)Cl)(=O)Cl XRPHFZRZETURBH-UHFFFAOYSA-N 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229940122440 HIV protease inhibitor Drugs 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
YRUMDWGUXBZEPE-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1.C1CCCCC1 YRUMDWGUXBZEPE-UHFFFAOYSA-N 0.000 description 1
ULNIIYXAXLNRIE-UHFFFAOYSA-N cyclohexane;2-methylpropan-2-ol Chemical compound CC(C)(C)O.C1CCCCC1 ULNIIYXAXLNRIE-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
238000011873 diastereoselective alkylation Methods 0.000 description 1
238000005906 dihydroxylation reaction Methods 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
ATMYQJHPCACNAV-UHFFFAOYSA-N ethyl acetate;propan-1-ol Chemical compound CCCO.CCOC(C)=O ATMYQJHPCACNAV-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
150000002241 furanones Chemical class 0.000 description 1
125000003844 furanonyl group Chemical group 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
238000000892 gravimetry Methods 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
DLDIDQIZPBIVNQ-UHFFFAOYSA-N hydron;2-methylpropan-2-amine;chloride Chemical compound Cl.CC(C)(C)N DLDIDQIZPBIVNQ-UHFFFAOYSA-N 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
150000005605 isobutyric acids Chemical class 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical class [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229910000487 osmium oxide Inorganic materials 0.000 description 1
JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
KIDBBTHHMJOMAU-UHFFFAOYSA-N propan-1-ol;hydrate Chemical compound O.CCCO KIDBBTHHMJOMAU-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
JZVKAQLAKHQCMA-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate N,N-diethylethanamine Chemical compound CCN(CC)CC.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JZVKAQLAKHQCMA-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Cephalosporin Compounds (AREA)
Catalysts (AREA)

CZ19962272A 1994-02-04 1995-01-30 Způsob racemizace opticky čistého nebo obohaceného piperazin-2-terc-butylkarboxamidového substrátu CZ291774B6 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19291694A	1994-02-04	1994-02-04

Publications (2)

Publication Number	Publication Date
CZ227296A3 CZ227296A3 (en)	1997-01-15
CZ291774B6 true CZ291774B6 (cs)	2003-05-14

Family

ID=22711555

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ19962272A CZ291774B6 (cs)	1994-02-04	1995-01-30	Způsob racemizace opticky čistého nebo obohaceného piperazin-2-terc-butylkarboxamidového substrátu

Country Status (20)

Country	Link
US (1)	US5663341A (de)
EP (1)	EP0741712B1 (de)
JP (1)	JPH09508628A (de)
KR (1)	KR100337579B1 (de)
AT (1)	ATE206407T1 (de)
AU (1)	AU691878B2 (de)
BR (1)	BR9506727A (de)
CA (1)	CA2180947A1 (de)
CZ (1)	CZ291774B6 (de)
DE (1)	DE69523038T2 (de)
ES (1)	ES2161863T3 (de)
FI (1)	FI112218B (de)
HU (1)	HUT76303A (de)
NZ (1)	NZ279734A (de)
RO (1)	RO118292B1 (de)
RU (1)	RU2135482C1 (de)
SK (1)	SK281861B6 (de)
TW (1)	TW472047B (de)
UA (1)	UA46730C2 (de)
WO (1)	WO1995021162A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL110255A (en) *	1993-07-16	1998-12-06	Merck & Co Inc	Formation and resolution of 2-tert-butylcarboxamido-piperazine
US5464788A (en) *	1994-03-24	1995-11-07	Merck & Co., Inc.	Tocolytic oxytocin receptor antagonists
WO1995029170A1 (en) *	1994-04-22	1995-11-02	Koei Chemical Co., Ltd.	Process for producing optically active n-tert-butyl-2-piperazinecarboxamide and method of racemizing the amide
US5792869A (en) *	1994-11-04	1998-08-11	Yamakawa Chemical Industry Co., Ltd	Process for preparing optically active piperazine derivatives and Intermediates for preparation
CA2208573C (en) *	1995-01-23	2008-08-05	Lonza Ag	Process for preparing 1,4,5,6-tetrahydropyrazine-2-carboxamides
US5618937A (en) *	1995-03-15	1997-04-08	Merck & Co., Inc.	Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
US5612484A (en) *	1995-05-18	1997-03-18	Merck & Co., Inc.	Process for making HIV protease inhibitors
DE19536658C2 (de) *	1995-09-30	1998-02-19	Degussa	Verfahren zur kontinuierlichen Herstellung von basischen, cyclischen, optisch aktiven alpha-Aminosäuren
CA2201218C (en) *	1996-04-23	2004-09-28	Rudolf Fuchs	Process for the preparation of optically active piperazine-2-carboxylic acid derivatives
WO2004071390A2 (en) *	2003-02-14	2004-08-26	Applied Research Systems Ars Holding N.V.	Piperazine-2-carboxamide derivatives
GB0314260D0 (en)	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB604185A (en) *	1940-08-08	1948-06-30	Arthur Mandl	Improvements in electric rectifier systems used in power or control systems such as for follow-up systems
US3692775A (en) *	1969-03-17	1972-09-19	Allied Chem	Racemization of d-or l-{60 -amino-caprolactam in the presence of metal ions
US3852351A (en) *	1972-10-02	1974-12-03	Fmc Corp	Chlorination of acetoacetamides
JPH01117869A (ja) *	1987-10-30	1989-05-10	Hokuriku Seiyaku Co Ltd	２−アミノメチルピペラジン誘導体
CA1340588C (en) *	1988-06-13	1999-06-08	Balraj Krishan Handa	Amino acid derivatives
US5413999A (en) *	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
DK0541168T3 (da) *	1991-11-08	1998-05-11	Merck & Co Inc	HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
MX9308016A (es) *	1992-12-22	1994-08-31	Lilly Co Eli	Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.

1995
- 1995-01-27 TW TW084100727A patent/TW472047B/zh not_active IP Right Cessation
- 1995-01-30 ES ES95908747T patent/ES2161863T3/es not_active Expired - Lifetime
- 1995-01-30 NZ NZ279734A patent/NZ279734A/en unknown
- 1995-01-30 CA CA002180947A patent/CA2180947A1/en not_active Abandoned
- 1995-01-30 WO PCT/US1995/001232 patent/WO1995021162A1/en not_active Ceased
- 1995-01-30 HU HU9602143A patent/HUT76303A/hu unknown
- 1995-01-30 CZ CZ19962272A patent/CZ291774B6/cs not_active IP Right Cessation
- 1995-01-30 AT AT95908747T patent/ATE206407T1/de not_active IP Right Cessation
- 1995-01-30 SK SK1006-96A patent/SK281861B6/sk unknown
- 1995-01-30 UA UA96093433A patent/UA46730C2/uk unknown
- 1995-01-30 RU RU96117468/04A patent/RU2135482C1/ru not_active IP Right Cessation
- 1995-01-30 BR BR9506727A patent/BR9506727A/pt active Search and Examination
- 1995-01-30 AU AU16967/95A patent/AU691878B2/en not_active Ceased
- 1995-01-30 JP JP7520686A patent/JPH09508628A/ja not_active Withdrawn
- 1995-01-30 DE DE69523038T patent/DE69523038T2/de not_active Expired - Fee Related
- 1995-01-30 EP EP95908747A patent/EP0741712B1/de not_active Expired - Lifetime
- 1995-01-30 RO RO96-01576A patent/RO118292B1/ro unknown
- 1995-01-30 KR KR1019960704219A patent/KR100337579B1/ko not_active Expired - Fee Related
- 1995-06-07 US US08/487,903 patent/US5663341A/en not_active Expired - Fee Related
1996
- 1996-08-01 FI FI963054A patent/FI112218B/fi active

Also Published As

Publication number	Publication date
FI963054L (fi)	1996-08-01
FI963054A0 (fi)	1996-08-01
ATE206407T1 (de)	2001-10-15
AU691878B2 (en)	1998-05-28
FI112218B (fi)	2003-11-14
CA2180947A1 (en)	1995-08-10
EP0741712A1 (de)	1996-11-13
HUT76303A (en)	1997-07-28
JPH09508628A (ja)	1997-09-02
NZ279734A (en)	1998-05-27
SK281861B6 (sk)	2001-08-06
KR100337579B1 (ko)	2002-11-13
EP0741712B1 (de)	2001-10-04
BR9506727A (pt)	1997-09-23
RO118292B1 (ro)	2003-04-30
WO1995021162A1 (en)	1995-08-10
AU1696795A (en)	1995-08-21
DE69523038D1 (de)	2001-11-08
DE69523038T2 (de)	2002-06-06
US5663341A (en)	1997-09-02
SK100696A3 (en)	1997-03-05
HU9602143D0 (en)	1996-09-30
UA46730C2 (uk)	2002-06-17
RU2135482C1 (ru)	1999-08-27
TW472047B (en)	2002-01-11
CZ227296A3 (en)	1997-01-15
MX9603218A (es)	1997-07-31
ES2161863T3 (es)	2001-12-16

Legal Events

Date	Code	Title	Description
2000-06-30	PD00	Pending as of 2000-06-30 in czech republic
2005-02-16	MM4A	Patent lapsed due to non-payment of fee	Effective date: 20040130

Publication	Publication Date	Title
AU2016299486A1 (en)	2017-11-09	1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JPH08511028A (ja)	1996-11-19	Ｐ物質拮抗剤としてのベンジルオキシキヌクリジン
EP3710437A1 (de)	2020-09-23	Enantiomerentrennung von racemischem nikotin durch zugabe eines o,o'-disubstituierten weinsäureenantiomers
IE922093A1 (en)	1992-12-30	4-pyrimidinecarboxamide derivatives, their preparation and¹their application in therapy
SK281861B6 (sk)	2001-08-06	Spôsob racemizácie opticky čistého substrátu 2-terc-butylkarboxamidpiperazínu alebo substrátu bohatého na 2-terc-butylkarboxamidpiperazín, alebo jeho solí a substrát na racemizáciu
EP1558580B1 (de)	2007-09-12	N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones als antimikrobielle mittel
SK283067B6 (sk)	2003-02-04	Spôsob výroby epoxidu
CZ293953B6 (cs)	2004-08-18	Způsob výroby meziproduktů pro výrobu inhibitorů HIV@proteázy a příslušné meziprodukty
EP2077837A2 (de)	2009-07-15	Derivate von pyrrolizin, indolizin und chinolizin, ihre herstellung und ihre therapeutische verwendung
CZ13096A3 (en)	1996-06-12	Process for preparing inhibitors of hiv-protease and intermediates for making the same
CZ266396A3 (cs)	1998-04-15	Regioselektivní způsob výroby cis-l-amino-2-indanolu
SK162795A3 (en)	1996-09-04	N-substituted azaheterocyclic carboxylic acids and esters thereof, preparation method thereof and pharmaceutical compositions containing them
CZ266196A3 (cs)	1998-02-18	Regioselektivní způsob výroby cis-1-amino-2-indanolu
CN110402245A (zh)	2019-11-01	外消旋3-烷基哌啶-羧酸乙酯的旋光异构体的分离方法
JPS6263556A (ja)	1987-03-20	アルキルアミノアミド誘導体、それらの製造方法及びそれらを含有する製薬組成物
MXPA96003218A (en)	1997-12-01	Procedure for making inhibitors of human immunodeficiency and composite intermediate virus proteas
EP2396334A1 (de)	2011-12-21	N-[(2-azabicyclo[2.1.1]hex-1-yl]arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung
EP2408763A2 (de)	2012-01-25	N-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamidderivate, ihre herstellung und anwendung für therapeutische zwecke
WO2010092287A1 (fr)	2010-08-19	Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique